Paper Details

  1. Home
  2. Paper Details

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.

Author: CamposVerena Ramirez, CohenJoshua M, NingXiaoping, PazderaLadislav, Pozo-RosichPatricia, YangRonghua

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fremanezumab demonstrated significant improvements in efficacy compared to placebo in patients with chronic or episodic migraine, even those with inadequate response to 4 prior preventive medication classes.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migraine preventive medications. METHODS: This is an exploratory analysis of a randomized, double-blind, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411464/

データ提供：米国国立医学図書館（NLM）

Fremanezumab: A Potential Oasis for Migraine Sufferers

The unrelenting pain of [illness] can feel like an endless desert. This research delves into the effectiveness of [specific drug] as a preventive treatment for migraine in patients who have not found relief from previous medications. The study explores the efficacy of [specific treatment regimen] in a diverse group of patients with [specific medical condition] who had previously experienced inadequate responses to [number] classes of preventive medications. The findings suggest that [specific drug] may offer a new hope for patients seeking relief from debilitating migraine symptoms.

A Glimpse of Relief: A Beacon in the Migraine Desert

The study revealed that [specific drug] resulted in significant improvements in [specific metric] compared to placebo in patients with [specific medical condition] who had previously failed to respond to [number] classes of migraine preventive medications. The researchers observed a [percentage] reduction in [specific metric] in the treatment group, indicating a potential breakthrough for this challenging condition.

Navigating the Migraine Landscape: A Guide to Hope

These findings provide a glimmer of hope for individuals struggling with chronic and episodic migraine, especially those who have not found success with traditional treatments. The study highlights the potential benefits of [specific drug] as a new and effective option for migraine prevention. It reinforces the importance of personalized treatment plans and the need for ongoing research to develop novel and effective therapies for this prevalent condition.

Dr.Camel's Conclusion

As a seasoned explorer of the medical desert, I am always seeking new remedies for the debilitating burdens of illness. This study offers a promising oasis of hope for migraine sufferers who have endured years of relentless pain. By embracing the potential of new therapies like fremanezumab, we can empower individuals to navigate the often-treacherous landscape of migraine with a renewed sense of hope and a chance to reclaim their lives.

Date :
  1. Date Completed 2021-12-08
  2. Date Revised 2021-12-14
Further Info :

Pubmed ID

33990144

DOI: Digital Object Identifier

PMC8411464

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.